WO2003032917A2 - Hookworm vaccine - Google Patents
Hookworm vaccine Download PDFInfo
- Publication number
- WO2003032917A2 WO2003032917A2 PCT/US2002/033106 US0233106W WO03032917A2 WO 2003032917 A2 WO2003032917 A2 WO 2003032917A2 US 0233106 W US0233106 W US 0233106W WO 03032917 A2 WO03032917 A2 WO 03032917A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- asp
- mtp
- hookworm
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention generally relates to a vaccine for hookworm.
- the invention provides vaccines based on parasite-derived antigens.
- Hookworm infection is a significant public health concern in developing countries around the world, causing enteritis, intestinal blood loss, anemia, developmental delays, and malnutrition. It is estimated that there are more than one billion cases of human hookworm infection worldwide, with 194 million cases in China alone (Hotez et al. 1997). In some regions of China such as Hainan province in the South China Sea more than 60 percent of the population harbor hookworms (Gandhi et al. 2001).
- Ancylostoma caninum is a major cause of morbidity and mortality in dogs throughout the world including subtropical regions of North America. Hookworm- associated blood loss leading to severe anemia and even death can occur in dogs between 2 and 3 weeks after a single primary infection (Soulsby, 1982; Jones and Hotez, 2002). Significantly, A. caninum has also been recently identified as an important human pathogen. Zoonotic infection with one adults, caninum parasite can result in eosinophilic enteritis syndrome, an inflammatory condition of the intestine in response to invasion by the parasite (Prociv and Croese, 1990). The pathogenesis of A. caninum infection is associated with the intestinal blood loss that occurs during adult worm attachment and feeding in the mammalian small intestine (Kalkofen, 1970; Kalkofen, 1974).
- the present invention provides preparations for eliciting an immune response against hookworm.
- the preparations contain various hookworm antigens which have been identified as useful for eliciting an immune response. These preparations may be used as vaccines against hookworm in mammals, for example, in humans.
- the vaccinated mammal may develop an immune response against hookworm which causes immunity to infection by the parasite, or may display a lower worm burden, decreased blood loss, or a decrease in size of parasitizing hookworms.
- the invention provides a composition comprising a recombinant or synthetic antigen or a fragment thereof derived from hookworm, and a pharmacologically acceptable carrier.
- the recombinant or synthetic antigen may display at least about 80% identity to an antigen such as Na-ASP-1, Na-ACE, Na-CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac-MTP-1, Ac-ASP-1, Ac-ASP-2, Ac-ASP-3, Ac-ASP-4, Ac-ASP-5, Ac-ASP-6, Ac-TTR-1, Ac-103, Ac-VWF, Ac-CTL, Ac-API, Ac-MTP-1, Ac-MTP-2, Ac-MTP-3, Ac-FAR-1, Ac-KPI-1, Ac- APR-1, Ac-APR-2, Ac-AP, Ay-ASP-1, Ay-ASP-2, Ay-MTP-1, Ay- API, or Ay-TTR.
- an antigen such as Na-ASP-1, Na-ACE, Na-CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac-MTP-1, Ac-ASP-1
- the antigen is Ac-TMP, Ac-MEP-1, or Ac-MTP-1.
- the antigens may be derived from a hookworm from species such as Necator americanus, Ancylostoma canium, Ancylostoma ceylancium, and Ancylostoma duodenale.
- the invention also provides a method of eliciting an immune response to hookworm in a mammal. The method includes the step of administering to the mammal an effective amount of a composition comprising a recombinant or synthetic antigen (or a fragment of the antigen) derived from hookworm, and a pharmacologically acceptable carrier.
- the recombinant or synthetic antigen may display at least about 80% identity to an antigen such as Na-ASP-1, Na-ACE, Na-CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac-MTP-1, Ac-ASP-1, Ac-ASP-2, Ac-ASP-3, Ac-ASP-4, Ac-ASP-5, Ac-ASP-6, Ac-TTR-1, Ac-103, Ac-VWF, Ac-CTL, Ac-API, Ac-MTP-1, Ac-MTP-2, Ac-MTP-3, Ac-FAR-1, Ac-KPI-1, Ac- APR-1, Ac-APR-2, Ac-AP, Ay-ASP-1, Ay-ASP-2, Ay-MTP-1, Ay-API, and Ay-TTR.
- an antigen such as Na-ASP-1, Na-ACE, Na-CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac-MTP-1, Ac-ASP
- the antigen is Ac-TMP, Ac-MEP-1, orAc-MTP-1.
- the antigens may be derived from a hookworm from species such as Necator americanus, Ancylostoma canium, Ancylostoma ceylancium, and Ancylostoma duodenale.
- the inventions further provides a method of vaccinating a mammal against hookworm.
- the method includes the step of administering to the mammal an effective amount of a composition comprising a recombinant or synthetic antigen (or a fragment of the antigen) derived from hookworm and a pharmacologically acceptable carrier.
- the recombinant or synthetic antigen may display at least about 80% identity with an antigen such as Na-ASP-1, Na-ACE, Na-CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac-MTP-1, Ac-ASP-1, Ac-ASP-2, Ac-ASP-3, Ac-ASP-4, Ac-ASP-5, Ac-ASP-6, Ac-TTR-1, Ac-103, Ac-VWF, Ac-CTL, Ac-API, Ac-MTP-1, Ac-MTP-2, Ac-MTP-3, Ac-FAR-1, Ac-KPI-1, Ac- APR-1, Ac-APR-2, Ac-AP, Ay-ASP-1, Ay-ASP-2, Ay-MTP-1, Ay-API, and Ay-TTR.
- an antigen such as Na-ASP-1, Na-ACE, Na-CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac-MTP-1, Ac-ASP
- the antigen is Ac-TMP, Ac-MEP-1, or Ac-MTP-1.
- the antigens may be derived from a hookworm from species such as Necator americanus, Ancylostoma canium, Ancylostoma ceylancium, and Ancylostoma duodenale.
- the invention further provides a composition comprising a recombinant or synthetic antigen (or a fragment of the antigen) derived from hookworm.
- the recombinant or synthetic antigen display at least about 80% identity with an antigen such as Na-ASP-1, Na-ACE, Na- CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac-MTP-1, Ac-ASP-1, Ac-ASP-2, Ac- ASP-3, Ac-ASP-4, Ac-ASP-5, Ac-ASP-6, Ac-TTR-1, Ac-103, Ac-VWF, Ac-CTL, Ac-API, Ac-MTP-1, Ac-MTP-2, Ac-MTP-3, Ac-FAR-1, Ac-KPI-1, Ac-APR-1, Ac-APR-2, Ac-AP, Ay-ASP-1, Ay-ASP-2, Ay-MTP-1 5 Ay-API, and Ay-TTR.
- an antigen such as Na-ASP-1, Na-ACE
- composition further comprises a pharmacologically acceptable carrier.
- the antigen is Ac-TMP, Ac-MEP-1, or Ac-MTP-1.
- the antigens may be derived from a hookworm from species such as Necator americanus, Ancylostoma canium, Ancylostoma ceylancium, and Ancylostoma duodenale.
- the invention further provides a vaccine comprising a recombinant or synthetic antigen (or a fragment of the antigen) derived from hookworm.
- the recombinant or synthetic antigen displays at least about 80% identity with an antigen such as Na-ASP-1, Na-ACE, Na- CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac-MTP-1, Ac-ASP-1, Ac-ASP-2, Ac- ASP-3, Ac-ASP-4, Ac-ASP-5, Ac-ASP-6, Ac-TTR-1, Ac-103, Ac-VWF, Ac-CTL, Ac-API, Ac-MTP-1, Ac-MTP-2, Ac-MTP-3, Ac-FAR-1, Ac-KPI-1, Ac-APR-1, Ac-APR-2, Ac-AP, Ay-ASP-1, Ay-ASP-2, Ay-MTP-1, Ay- API, and Ay-TTR,
- the vaccine further comprises a pharmacologically acceptable carrier.
- the antigen is Ac-TMP, Ac- MEP-1, or Ac-MTP-1.
- the antigens may be derived from a hookworm from species such as Necator americanus, Ancylostoma canium, Ancylostoma ceylancium, and Ancylostoma duodenale.
- the present invention further provides a composition for eliciting an immune response comprising a recombinant or synthetic antigen (or a fragment of the antigen) derived from hookworm.
- the recombinant or synthetic antigen displays at least about 80% identity with an antigen selected from the group consisting of Na-ASP-1, Na-ACE, Na-CTL, Na- APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac-MTP-1, Ac-ASP-1, Ac-ASP-2, Ac-ASP-3, Ac-ASP-4, Ac-ASP-5, Ac-ASP-6, Ac-TTR-1, Ac-103, Ac-VWF, Ac-CTL, Ac-API, Ac- MTP-1, Ac-MTP-2, Ac-MTP-3, Ac-FAR-1, Ac-KPI-1, Ac-APR-1, Ac-APR-2, Ac-AP, Ay- ASP-1, Ay-ASP-2, Ay-MTP-1, Ay- API, and Ay-TTR.
- composition further comprises a pharmacologically acceptable carrier.
- the antigen is Ac-TMP, Ac- MEP-1, orAc-MTP-1.
- the antigens may be derived from a hookworm from species such as Necator americanus, Ancylostoma canium, Ancylostoma ceylancium, and Ancylostoma duodenale.
- the invention further provides a method for enabling vaccination of a patient against infectious diseases.
- the method includes the steps of treating hookworm infection to a degree sufficient to increase lymphocyte proliferation, and vaccinating the patient against an infectious disease such as HIV, tuberculosis, malaria, measles, tetanus, diphtheria, pertussis, or polio.
- the present invention also provides a method for enabling hookworm vaccination.
- the method includes the steps of chemically treating a hookworm infected patient to ameliorate hookworm infection, and vaccinating the patient with a recombinant or synthetic antigen (or a fragment of the antigen) derived from hookworm after amelioration of hookworm infection.
- the hookworm infection may be completely eradicated by treatment, or may be lessened to such an extent that hookworm vaccination is effective.
- the recombinant or synthetic antigen may display at least about 80% identity with an antigen such as Na-ASP-1, Na-ACE, Na-CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac- MTP-1, Ac-ASP-1, Ac-ASP-2, Ac-ASP-3, Ac-ASP-4, Ac-ASP-5, Ac-ASP-6, Ac-TTR-1, Ac- 103, Ac-VWF, Ac-CTL, Ac-API, Ac-MTP-1, Ac-MTP-2, Ac-MTP-3, Ac-FAR-1, Ac-KPI-1, Ac-APR-1, Ac-APR-2, Ac-AP, Ay-ASP-1, Ay-ASP-2, Ay-MTP-1, Ay- API, and Ay-TTR.
- an antigen such as Na-ASP-1, Na-ACE, Na-CTL, Na-APR-1, NA-APR-2, Ac-TMP, Ac-MEP-1, Ac- MTP-1, Ac-ASP
- the present invention also provides a method for reducing blood loss in a patient infected with hookworm.
- the method includes the step of administering to the patient a composition comprising a recombinant or synthetic antigen (or a fragment of the antigen) derived from hookworm, and a pharmacologically acceptable carrier.
- the present invention also provides a method for reducing hookworm size in a patient infected with hookworm.
- the method includes the step of administering to the patient a composition comprising a recombinant or synthetic antigen (or a fragment of the antigen) derived from hookworm, and a pharmacologically acceptable carrier.
- the invention further provides a method of reducing hookworm burden in a patient infected with hookworm.
- the method comprises the step of administering to the patient a composition comprising a recombinant or synthetic antigen (or a fragment of the antigen) derived from hookworm, and a pharmacologically acceptable carrier.
- the present invention also provides the following nucleic acid and amino acid sequences: SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 25, SEQ ID NO. 26, SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 29, SEQ ID NO. 30, SEQ ID NO. 31, SEQ ID NO. 32, SEQ ID NO. 33, SEQ ID NO.
- SEQ ID NO. 35 SEQ ID NO. 36, SEQ ID NO. 37, SEQ ID NO. 38, SEQ ID NO. 39, SEQ ID NO. 40, SEQ ID NO. 41, SEQ ID NO. 42, SEQ ID NO. 43, SEQ ID NO. 44, SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 49, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52, SEQ ID NO. 55, SEQ ID NO. 56, SEQ ID NO. 57, SEQ ID NO. 58, SEQ ID NO. 59, SEQ ID NO. 60, SEQ ID NO. 61, SEQ ID NO. 62, SEQ ID NO. 63 and SEQ ID NO. 64.
- Figure 1A and B Na-ASP-1 : A, cDNA (SEQ ID NO. 1) and B, deduced amino acid sequence (SEQ ID NO. 2). GeneBank accession # AF079521.
- Figure 2A and B Na-ACE: A, cDNA (SEQ ID NO. 3) and B, deduced amino acid sequence
- Figure 3A and B Na-CTL: A, cDNA (SEQ ID NO. 5) and B, deduced amino acid sequence
- Figure 4A and B Na-APR-1 : A, cDNA (SEQ ID NO. 7) and B, deduced amino acid sequence (SEQ ID NO. 8).
- Figure 5A and B Na-APR-2: A, cDNA (SEQ ID NO. 9) and B, deduced amino acid sequence (SEQ ID NO. 10).
- FIG. 6A and B Ac-TMP: A, cDNA (SEQ ID NO. 11) and B, deduced amino acid sequence (SEQ ID NO.12).
- FIG. 7A and B Ac-MEP-1: A, cDNA (SEQ ID NO. 13) and B, deduced amino acid sequence (SEQ ID NO.14). GeneBank accession # AF273084.
- FIG. 8A and B Ac-MTP-1: A, cDNA (SEQ ID NO. 15) and B, deduced amino acid sequence (SEQ ID NO. 16). GeneBank accession # AY036056.
- FIG. 9A and B Ac-ASP-1 : A, cDNA (SEQ ID NO. 17) and B, deduced amino acid sequence (SEQ ID NO. 18). GeneBank accession * AF 132291.
- FIG. 10A and B Ac-ASP-2: A, cDNA (SEQ ID NO. 19) and B, deduced amino acid sequence (SEQ ID NO. 20). GeneBank accession # AF089728.
- FIG 11A and B Ac-ASP-3: A, cDNA (SEQ ID NO. 21) and B, deduced amino acid sequence (SEQ ID NO. 22).
- FIG 12A and B. Ac-ASP-4: A, cDNA (SEQ ID NO. 23) and B, deduced amino acid sequence (SEQ ID NO. 24).
- Figure 13A and B. Ac-ASP-5: A, cDNA (SEQ ID NO. 25) and B, deduced amino acid sequence (SEQ ID NO. 26).
- FIG. 14A and B Ac-ASP-6: A, cDNA (SEQ ID NO. 27) and B, deduced amino acid sequence (SEQ ID NO. 28).
- FIG. 15 A and B.
- Ac-TTR A, cDNA (SEQ ID NO. 29) and B, amino acid sequence (SEQ ID NO.
- FIG. 20A and B Ac-MTP-1 : A, cDNA (SEQ ID NO. 39) and B, amino acid sequence
- FIG. 25A and B Ac-APR-1 : A, cDNA (SEQ ID NO. 49) and B, amino acid sequence
- FIG. 26A and B Ac-APR-2: A, partial cDNA sequence (SEQ ID NO. 51) and B, partial amino acid sequence (SEQ ID NO. 52).
- FIG. 28A and B Ay-ASP-1 : A, cDNA (SEQ ID NO. 55) and B, amino acid sequence (SEQ ID NO. 56).
- FIG. 29A and B Ay-ASP-2: A, cDNA (SEQ ID NO. 57) and B, amino acid sequence (SEQ ID NO. 58).
- FIG. 30A and B Ay-MTP-1: A, cDNA (SEQ ID NO. 59) and B, amino acid sequence (SEQ ID NO. 60).
- FIG. 31A and B Ay-API-1 : A, cDNA (SEQ ID NO. 61) and B, amino acid sequence (SEQ ID NO. 62) deduced from nucleotides 23-703.
- Ay-TTR A, partial cDNA (SEQ ID NO. 63) and B, partial amino acid sequence (SEQ ID NO. 64).
- Figure 33A and B Spearman rank order correlations between hookworm burden and anti-MTP-1 antibody titer. A) total worms; B) median EPG.
- FIG 34A-C Antigen-specific geometric mean IgGl antibody titers in dogs vaccinated with A. caninum recombinant fusion proteins as a function of time. Geometric means were calculated for a total of 6 dogs in each group, except for Ac-AP in which only a single dog developed an antigen-specific antibody response. The arrows denote timed vaccinations.
- Figure 35 Female and male adult A. caninum hookworms recovered from the colons of either vaccinated or alum-injected dogs.
- Figure 36A and B Spearman rank order correlations between hookworm burden and anti-MTP-1 antibody titer
- FIG. 37A and B A) Relationship between anti-TTR IgE antibodies and hookworm burden reductions; B) Relationship between anti-TTR IgGl antibodies and hookworm burden reductions
- Figure 39 Statistically significant reduction in worm size (between 1 and 2 mm) among the TTR vaccinated group relative to the adjuvant control group.
- FIG 40 CD4+ lymphocytes from hookworm-infected (egg positive) individual post- stimulation with Ancylostoma L3 antigen.
- Figure 41 CD4+ lymphocytes from hookworm-infected (egg positive) individual post- stimulation with Pichia-expresses recombinant Na-ASP-1.
- compositions for use in eliciting an immune response to hookworm in a mammal Such compositions may be utilized as vaccines for use in the treatment and/or prevention of hookworm infection.
- the vaccines comprise purified preparations of antigens which are derived from hookworm, and a pharmacologically acceptable carrier.
- derived from we mean that the antigen is a biomolecule that originated from (i.e. was isolated from) a hookworm.
- the antigen may be a protein, a polypeptide, or an antigenic fragment of a protein, or polypeptide, which constitutes part of a hookworm organism.
- such an antigen is isolated and at least partially purified from a hookworm by methods which are well known to those of skill in the art (for example, see Examples section below).
- such antigens When manufactured for use in eliciting an immune response or as a vaccine, such antigens may be "synthetic" i.e. obtained synthetically (e.g. by peptide synthesis in the case of polypeptides and protein fragments), or "recombinant” i.e. obtained by genetic engineering techniques (e.g. by production in a host cell which harbors a vector containing DNA which encodes the antigen).
- yeast e.g. Pichia pastor is
- baculovirus/insect cells plant cells, and mammalian cells, and.
- the antigens are expressed in a yeast or baculovirus/insect cell expression system.
- variants may exist or be constructed which display: conservative amino acid substitutions; non-conservative amino acid substitutions; truncation by, for example, deletion of amino acids at the amino or carboxy terminus, or internally within the molecule; or by addition of amino acids at the amino or carboxy terminus, or internally within the molecule (e.g.
- variants may be naturally occurring (e.g. as a result of natural variations between species or between individuals); or they may be purposefully introduced (e.g. in a laboratory setting using genetic engineering techniques). All such variants of the sequences disclosed herein are intended to be encompassed by the teaching of the present invention, provided the variant antigen displays sufficient identity to the described sequences.
- identity will be in the range of about 50 to 100%, and more preferably in the range of about 75 to 100%), and most preferably in the range of about 80 to 100% of the disclosed sequences.
- the identity is with reference to the portion of the amino acid sequence that corresponds to the original antigen sequence, i.e. not including additional elements that might be added, such as those described below for chimeric antigens.
- the invention also encompasses chimeric antigens, for example, antigens comprised, of the presently described amino acid sequences plus additional sequences which were not necessarily associated with the disclosed sequences when isolated but the addition of which conveys some additional benefit.
- benefit may be utility in isolation and purification of the protein, (e.g. histidine tag, GST, and maltose binding protein); in directing the protein to a particular intracellular location (e.g. yeast secretory protein); in increasing the antigenicity of the protein (e.g. KHL, haptens).
- All such chimeric constructs are intended to be encompassed by the present invention, provided the portion of the construct that is based on the sequences disclosed herein is present in at least the indicated level of homology.
- a fragment of the protein is adequate to confer immunization.
- the present invention also encompasses antigenic fragments of the sequences disclosed herein, and their use in vaccine preparations. In general, such a fragment will be at least about 10-13 amino acids in length.
- suitable sequences are often hydrophilic in nature, and are f equently surface accessible.
- nucleic acid sequences disclosed herein those of skill in the art will recognize that many variants of the sequences may exist or be constructed which would still function to provide the encoded antigens or desired portions thereof. For example, due to the redundancy of the genetic code, more than one codon may be used to code for an amino acid. Further, as described above, changes in the primary sequence of the antigen may be desired, and this would necessitate changes in the encoding nucleic acid sequences. In addition, those of skill in the art will recognize that many variations of the nucleic acid sequences may be constructed for purposes related to cloning strategy, (e.g.
- nucleic acid sequences for ease of manipulation of a sequence for insertion into a vector, such as the introduction of restriction enzyme cleavage sites, etc.), for purposes of modifying transcription (e.g. the introduction of promoter or enhancer sequences, and the like), or for any other suitable purpose.
- All such variants of the nucleic acid sequences disclosed herein are intended to be encompassed by the present invention, provided the sequences display about 50 to 100% identity to the original sequence and preferably, about 75 to 100% identity, and most preferably about 80 to 100%) identity.
- the identity is with reference to the portion of the nucleic acid sequence that corresponds to the original sequence, and is not intended to cover additional elements such as promoters, vector-derived sequences, restriction enzyme cleavage sites, etc. derived from other sources.
- the antigens of the present invention may be derived from any species of hookworm, examples of which include but are not limited to Necator americanus, Ancylostoma canium, Ancylostoma ceylancium and Ancylostoma duodenale.
- hookworm antigens include but are not limited to Na-ASP-1, Na-ACE, Na-CTL, Na- APR- 1 , NA-APR-2, Ac-TMP, Ac-MEP- 1 , Ac-MTP- 1 , Ac-ASP- 1 , Ac-ASP-2, Ac-ASP-3, Ac-ASP-4, Ac-ASP-5, Ac-ASP-6, Ac-TTR-1, Ac-103, Ac-VWF, Ac- CTL, Ac-API, Ac-MTP-1, Ac-MTP-2, Ac-MTP-3, Ac-FAR-1, Ac-KPI-1, Ac-APR-1, Ac- APR-2, Ac-AP, Ay-ASP-1, Ay-ASP-2, Ay-MTP-1, Ay- API, and Ay-TTR.
- the antigenic entity is an activation associated secretory protein, examples of which include but are not limited to Na-ASP-1, Ac-ASP-3, Ac-ASP-4, Ac-ASP-5, Ac-ASP-6, Ay-ASP-1, and Ay-ASP-2.
- the antigenic moiety is a protease, examples of which include but are not limited to metalloproteases (e.g. Ac-MTP-2, Ac-MTP-3; cysteine proteases; aspartic proteases (e.g. Ac-APR-1 and Ac-APR-2); and serine proteases.
- metalloproteases e.g. Ac-MTP-2, Ac-MTP-3
- cysteine proteases e.g. Ac-APR-1 and Ac-APR-2
- serine proteases e.g. Ac-APR-1 and Ac-APR-2
- the antigen may be a lectin (e.g. Na-CTL, Ac-CTL).
- the antigen may be a protease inhibitor (e.g. Ac-API-1, Ay-API-1, Ac-AP, Ac-KPI-1).
- a protease inhibitor e.g. Ac-API-1, Ay-API-1, Ac-AP, Ac-KPI-1).
- the antigen utilized in the practice of the present invention is Ac-TMP, the DNA encoding sequence of which is given in Figure 6 A (SEQ ID NO. 11), and the amino acid sequence of which is given in Figure 6B (SEQ ID NO. 12).
- the antigen utilized in the practice of the present invention is Ac-MEP-1, the DNA encoding sequence of which is given in Figure 7 A (SEQ ID NO. 13, and the amino acid sequence of which is given in Figure 7B (SEQ ID NO. 14).
- the antigen utilized in the practice of the present invention is Ac-MTP-1
- the DNA encoding sequence of wliich is given in Figure 8 A (SEQ ID NO. 15, and the amino acid sequence of which is given in Figure 8B (SEQ ID NO. 16).
- Suitable antigens include but are not limited to Na-CTL (SEQ ID NOS. 5-6); Na-APR-1 (SEQ ID NOS. 7-8); Na-APR-2 (SEQ ID NOS. 9-10); Ac-TMP (SEQ ID NOS. 11-12); Ac-ASP-3 (SEQ ID NOS. 21-22); Ac-ASP-4 (SEQ ID NOS. 23-24); Ac-ASP-5 (SEQ ID NOS. 25-26); Ac-ASP-6 (SEQ ID NOS. 27-28); Ac-TTR (SEQ ID NOS. 29-30); Ac-103 (SEQ ID NOS. 31-32); Ac-VWF (SEQ ID NOS. 33-34); Ac-CTL (SEQ ID NOS.
- the present invention provides compositions for use in eliciting an immune response which may be utilized as a vaccine against hookworm.
- eliciting an immune response we mean that an antigen stimulates synthesis of specific antibodies at a titer of about >1 to about 1 x 10 6 or greater.
- the titer is from about 10,000 to about 1 x 10 6 or more, and most preferably, the titer is greater than 1 x 10 6 , as measured by, for example, 3 H thymidine incorporation.
- vaccine we mean an antigen that elicits an immune response that results in a decrease in hookworm burden of a least about 30% in an organism in relation to a non- vaccinated (e.g. adjunct alone) control organism.
- the level of the decrease is about 50%, and most preferably, about 60 to about 70%) or greater.
- compositions for use in eliciting an immune response which may be utilized as a vaccine against hookworm.
- the compositions include a substantially purified hookworm antigen or variant thereof as described herein, and a pharmacologically suitable carrier.
- the preparation of such compositions for use as vaccines is well known to those of skill in the art. Typically, such compositions are prepared either as liquid solutions or suspensions, however solid forms such as tablets, pills, powders and the like are also contemplated. Solid forms suitable for solution in, or suspension in, liquids prior to administration may also be prepared. The preparation may also be emulsified.
- the active ingredients may be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredients.
- Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol and the like, or combinations thereof.
- the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like.
- the composition may contain other adjuvants. If it is desired to administer an oral form of the composition, various thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders and the like may be added.
- the composition of the present invention may contain any such additional ingredients so as to provide the composition in a form suitable for administration.
- the final amount of hookworm antigen in the formulations may vary. However, in general, the amount in the formulations will be from about 1-99%.
- the vaccine preparations of the present invention may further comprise an adjuvant, suitable examples of which include but are not limited to Seppic, Quil A, Alhydrogel, etc.
- the preparations of the present invention may contain a single hookworm antigen.
- more than one hookworm antigen may be utilized in a preparation, i.e. the preparations may comprise a "cocktail" of antigens.
- the present invention also provides method of eliciting an immune response to hookworm and methods of vaccinating a mammal against hookworm.
- administration of the antigen causes the synthesis of specific antibodies (at a titer in the range of 1 to 1 x 10 6 , preferably 1 x 10 3 , more preferable in the range of about 1 x 10 3 to about 1 x 10 6 , and most preferably greater than 1 x 10 6 ) and/or cellular proliferation, as measured, e.g. by 3 H thymidine incorporation.
- the methods involve administering a composition comprising a hookworm antigen in a pharmacologically acceptable carrier to a mammal.
- the vaccine preparations of the present invention may be administered by any of the many suitable means which are well known to those of skill in the art, including bu not limited to by injection, orally, intranasally, by ingestion of a food product containing the antigen, etc.
- the mode of administration is subcutaneous or intramuscular.
- the present invention provides methods to elicit an immune response to hook worn and to vaccinate against hookworm in mammals.
- the mammal is a human.
- the preparations may also be used for veterinary purposes. Examples include but are not limited to companion "pets" such as dogs, cats, etc.; food source, work and recreational animals such as cattle, horses, oxen, sheep, pigs, goats, and the like.
- the antigen which is utilized will be derived from a species of hookworm which parasitizes the species of interest.
- antigens from Necator americanus may be preferred for the immunization of humans
- antigens from Ancylostoma canium may be preferred for the immunization of dogs.
- Ancylostoma canium is known to parasitize humans as well as its primary canine host.
- cross- species hookworm antigens may sometimes be highly effective in eliciting an immune response in a non-host animal, i.e. in an animal that does not typically serve as host for the parasite from which the antigen is derived. Rather, the measure of an antigen's suitability for use in an immune-stimulating or vaccine preparation is dependent on its ability to confer protection against invasion and parasitization by the parasite as evidenced by, for example, hookworm burden reduction or inhibition of hookworm associated blood loss (e.g. as measured by hematocrit and/or hemoglobin concentration.
- an antigen upon administration results in a reduction in worm burden of at least about 30%o, preferably at least about 50%, and most preferably about 60 to about 70%>.
- a method for enabling vaccination of a patient against infectious diseases involves treating hookworm infection to a degree sufficient to increase lymphocyte proliferation, followed by vaccinating the patient against said infectious disease.
- the method is based on evidence provided in Example 10 which shows that hookworm infestation causes anergy to hookworm and possibly other antigen stimulation. Therefore, by chemically treating hookworm infected patients prior to vaccination against hookworm or any infectious agent, the response to the vaccination will be improved.
- infectious diseases against which vaccination outcomes may be improved include but are not limited to HIN, tuberculosis, malaria, and routine childhood vaccinations (e.g. measles, tetanus, diphtheria, pertussis, polio, and the like).
- agents with which hookworm may be chemically treated include but are not limited to albendazole and other antihelminthic drugs.
- Certain of the antigens described herein may also be useful in the treatment of other neoplastic, autoimmune, and cardiovascular conditions, as well as for the treatment of pro- inflammatory states.
- Such uses of other hookworm antigens have been described in, for example, United States patent 5,427,937 to Capello et al. and United States patent 5,753,787 to Hawdon.
- the present invention also provides the following nucleic acid and amino acid sequences: SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 25, SEQ ID NO. 26, SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 29, SEQ ID NO. 30, SEQ ID NO. 31, SEQ ID NO. 32, SEQ ID NO. 33, SEQ ID NO.
- SEQ ID NO. 35 SEQ ID NO. 36, SEQ ID NO. 37, SEQ ID NO. 38, SEQ ID NO. 39, SEQ ID NO. 40, SEQ ID NO. 41, SEQ ID NO. 42, SEQ ID NO. 43, SEQ ID NO. 44, SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 49, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52, SEQ ID NO. 55, SEQ ID NO. 56, SEQ ID NO. 57, SEQ ID NO. 58, SEQ ID NO. 59, SEQ ID NO. 60, SEQ ID NO. 61, SEQ ID NO. 62, SEQ ID NO. 63 and SEQ ID NO. 64.
- sequences represent cDNA sequences and the amino acid sequences (open reading frames) wliich they encode. While the sequences themselves are being claimed, other sequences with a high level of identity in comparison to those described are also contemplated, e.g. sequences having at least about 65 to 100%) identity, or preferably about 75 to 100% identity, or most preferably at least about 80 to 100% identity, to the sequences that are given.
- sequences for Ac-APR-2 (SEQ ID NOS. 51 and 52) and Ay-TTR (SEQ ID NOS. 63 and 64) are partial sequences which represent the majority of the antigen sequence.
- the present invention encompasses the entire Ac-APR-2 antigen and the entire Ay-TTR antigen.
- Ay-TTR antigen which is provided in the present application is representative of the Ay-TTR family of antigens present in many species of nematodes.
- an Ay-TTR antigen from any nematode is intended to be encompassed by the present invention.
- any Ay-TTR antigen derived from a hookworm species including but not limited to Necator americanus, Ancylostoma canium, Ancylostoma ceylancium, and Ancylostoma duodenale, are encompassed.
- EXAMPLES Example 1. Molecular Cloning and Purification of Ac-TMP Materials and Methods.
- Immunoscreening of adult A. caninum library Preparation of anti- A. caninum secretory product antibody.
- One hundred living adult stage Ancylostoma caninum hookworms were recovered from the intestines of an infected dog, at necropsy (6 weeks post-infection), as described previously (Hotez and Cerami, 1983).
- the adult worms were washed three times in sterile PBS, then maintained in 15 ml RPM 1640 containing 25 mM HEPES, 100 units/ml of ampicillin and 100 ⁇ g/ml streptomycin at 37C (5%> CO 2 ) for 24 hours.
- the supernatant was collected, concentrated with PEG6000, and dialyzed against 1 L phosphate buffered saline (pH 7.2) overnight at 4C. Following dialysis, the secreted products were centrifuged at 10,000xg for 10 min, and the supernatant was recovered.
- a rabbit was immunized by subcutaneous injection with the hookworm-secreted proteins (400 ug) emulsified with complete Freund's adjuvant. Subsequently, the rabbit was immunized at two week intervals with the same quantity of hookworm secreted proteins emulsified with incomplete Freund's adjuvant for a total of three immunizations. The final bleed was obtained 10 days after the final immunizations, and the serum was separated from whole blood and stored at -20C.
- ZapII (Stratagene, La Jolla CA) library was reported previously (Capello et al, 1996)).
- A. caninum antigen expression was induced by covering the plaques with nitrocellulose membranes soaked with 10 mM IPTG. Four hours after incubation at 37C, the membranes were lifted, blocked with 5% non-fat milk in PBS, and then incubated with the rabbit antibody (1 :500 dilution) for 1 hour at 24C.
- the membranes were washed three times with PBS buffer containing 0.1% Tween-20 (PBS-Tween) and then incubated with horseradish peroxidase conjugated goat anti-rabbit IgG (Sigma) at a 1 : 1000 dilution at 24C for another hour.
- the membranes were washed again three times with PBS-Tween and then developed with 3,3'-diaminobenzidine (DAB) substrate and hydrogen peroxide.
- DAB 3,3'-diaminobenzidine
- the immunopositive clones were excised into pBluscript phage according to manufacturer's instructions (Stratagene), Phagemid DNA was extracted using the alkaline lysis method (Qiagen) and double strand sequencing was performed using flanking vector primers (T 3 and T 7 ). Nucleotide and deduced amino acid sequences were compared to existing sequences in GenBank by BLAST searching. ESEE 3.1 software was used for sequence analysis. Reverse transcription polymerase chain reaction fRT-PCR') amplification.
- RT-PCR was used to determine the developmental stage specificity of Ac-tmp mRNA transcription.
- PCR reaction parameters were comprised of 94C denaturing for 1 min, 55C annealing for 1 min, 72C extension for 2 min. A total 30 cycles were performed.
- YMC-Pack Protein-RP 200A, 5 ⁇ m C 4 Column (Waters).
- the adults, caninum secretory products used as starting material were collected over 15 hr from 1260 adult hookworms in 15 ml RPMI 1640 containing 25 mM HEPES, 100 units/ml ampicillin, 100 ⁇ g/ml streptomycin and 100 ⁇ g/ml gentamicin at 37C.
- the supernatant was concentrated by ultrafiltration in a Centricon-3 microconcentrator (Amicon) to 0.3 vol. before centrifugation for 1 hr at 7,500 x g. Approximately 0.6 mg of the parasite secretory protein was chromatographed.
- Eluent A was 0.01% Trifluoroacetic acid (TFA) in water, and eluent B was 0.01%) TFA in acetonitrile.
- a 40-min linear aradient from 0-80% B was run at a flow-rate of 1 ml/min. Fractions of 0.5 min were collected, lyophilized, and were used for further purification and analysis by SDS-PAGE (Laemmli, 1970).
- SDS-PAGE 2 ⁇ l of secretory products as well as the 10 ⁇ l of HPLC isolated fraction number 51 were mixed with the same volume of 2X SDS-PAGE sample buffer (4% SDS, 2.5% 2- mercapto ethanol, 15% glycerol) and boiled for 5 min. The samples were run on a 4-20%> gradient SDS-PAGE gel at 100 V for 2 hours. The gel was stained with silver according to manufacturer's instruction (BIO-RAD).
- Fraction 51 the fraction that contained the most abundant ⁇ , caninum. secretory protein from the semi-preparative separation, was carried out on a 510 HPLC system equipped as described above using a 250 mm. x 3.0 I.D. YMC protein RP, 200 A, 5 ⁇ m C4 column. Eluent A was 0.01% TFA in water, and B was 0.01% TFA in acetonitrile. A 30-min linear gradient from 0-60% B was run at a flow-rate of 1 ml/min. Fractions of 0.5 min were collected and lyophilized. The major protein peak collected from this separation was subjected to amino acid sequence analysis and SDS-PAGE (Laemmli, 1970).
- degenerate oligonucleotide primers were synthesized in both orientations that corresponding to the partial N-terminal peptides sequence of fraction number 51. Paired flanking degenerate vector primers were used to amplify the product from DNA obtained from the adult cDNA library constructed in ZapII .
- the "hot start" PCR conditions were 10 mM Tris-HCl (pH 8.5) containing 50 mM KC1, 2.0 mM MgCl 2 , 0.2 mM of each dNTP, and 1 ⁇ l cDNA library, in 20 ⁇ l reaction.
- the reactions were heated at 94C for 5 min, then lowered to 85C for 5 min, then 1 unit of Taq DNA polymerase (GIBCO BRL) was added. This was followed by 30 cycles of 1 min of denaturation at 94C, 1 min of annealing at 55C, and 2 min of extension at 72C.
- the PCR products were run on an agarose gel and stained with ethidium bromide.
- the PCR products were gel purified with the QIAEX II Gel Extraction kit (Qiagen, Valencia, CA), and sequenced.
- Ac-TMP cDNA was cloned from an adult hookworm cDNA library by immunoscreening with rabbit antibody directed against whole A.caninum adult secretory products. Two positive identical clones were isolated.
- the full-length cDNA consists of 559 bps (SEQ ID NO. 11) encoding an open reading frame (ORF) of 140 amino acids (SEQ ID NO. 12) and a poly-A tail at the 3' end.
- ORF open reading frame
- the predicted ORF has a calculated molecular weight of 16,100 daltons and a theoretical pi of 7.55.
- Ac-TMP has a signature N terminal Cys-X-Cys sequence immediately following the signal peptide.
- N-X-T One putative N linked glycosylation site exists between amino acids 119 and 122 (Fig.6B).
- GenBank database searching revealed that the predicted amino acid sequence of this molecule shares 33 percent identity and 50 percent similarity to the N-terminal domain of human tissue inhibitor of metalloproteinase 2 (TIMP-2).
- TIMP-2 human tissue inhibitor of metalloproteinase 2
- Both Ac-TMP and a putative TIMP from the free-living nematode Caenorhabditis elegans are comprised of a single domain and lack a second, C-terminal domain that is characteristic of vertebrate TIMPs (data not shown).
- RT-PCR amplification To identify the life-history stage specific expression of Ac-TMP, mRNAs were extracted from different developmental stages of A.caninum and reverse transcribed to cDNA with Ac-TMP specific primers.
- RT-PCR produced a 380 bp specific band that was only amplified from adult cDNA. No amplification was seen from the cDNA of eggs, Li-L2 and L3 life history stages. Amplification of A. caninum genomic DNA revealed two bands suggestive of a possible intron or the existence of a second, related Ac-TMP gene (data not shown).
- the N- terminal peptide sequence (20 amino acids) of this fraction was an identical match with the sequence of the predicted ORF of Ac-TMP after the predicted signal peptidase cleavage site. Based on the calculated area under the curve of HPLC peak 51 relative to the total area of the entire secretory product profile, Ac-TMP was determined to comprise approximately 6.3 percent of the total A. caninum secretory products. This identified the molecule as one of the most abundant proteins released by adult caninum. The abundance of Ac-TMP in hookworm secretory products was confirmed by visual inspection on SDS-PAGE. Paired degenerate primers based on the sequence of the first seven amino acids were used to construct PCR products from the adult hookworm cDNA library. DNA sequence of the PCR products confirmed the identity to Ac-TMP cDNA (data not shown).
- TMP is the most abundant protein secreted by hookworms and that the protein has been cloned and expressed, and the recombinant protein isolated.
- A. caninum parasites were maintained in beagles as described previously (Schad 1982). Third stage infective larvae (L3) were isolated from charcoal copro-cultures and stored in BU buffer (Hawdon et al. 1995). Adult caninum worms were collected from infected dogs upon necropsy. These worms were washed three times in PBS, snap frozen in liquid nitrogen, and stored at -80 ° C.
- Genomic DNA was isolated from adults, caninum by standard methods (Ausubel et al. 1993).
- A. caninum RNA was isolated by grinding previously frozen (-80 °C) adult worms in the presence of Trizol reagent (Gibco BRL) and following manufacturers protocol.
- cDNA was prepared from RNA by the ProSTAR First Strand RTPCR Kit (Stratagene) according to the manufacturer's instructions.
- A. caninum genomic and cDNA libraries An A. caninum genomic DNA library was constructed as follows: 3Q ugA. caninum genomic DNA was partially digested (37 °C for 5 min) by 8 U Sau3A restriction enzyme (NEB) in a 100 ul volume with recommended buffer. The digested DNA was then ethanol precipitated and pelleted by standard methods. The resulting pellet was dried, dissolved in water, and ligated into the Lambda-FIXII vector (Stratagene) according to manufacture's protocol. This ligation reaction was then packaged with Gigapack Gold packaging extract (Stratagene) and amplified. An A. caninum adult cDNA library was constructed previously (Capello et al. 1996) in lambda ZAPII (Stratagene) vector.
- MP-3 was amplified with T3 and MEP-R2 primers.
- the 5 '-RACE kit from GibcoBRL was employed to identify the 5' end of Ac-mep-l .
- first strand cDNA was produced in a reverse transcription reaction with the Ac-mep-l specific primer RACE-Rl on freshly prepared RNA.
- This cDNA was then poly C tailed at its 3' end with terminal deoxytransferase and used as template in a PCR reaction with anchor primer AAP (GibcoBRL) and gene specific reverse primer MEP-R2.
- the resulting products were diluted and used as template in a hemi-nested PCR reaction with anchor primer UAP (GibcoBRL) and gene specific primer MEP-R3.
- the PCR product generated was cloned and termed MP-4.
- G-MEP genomic DNA clone
- Multiple clones were sequenced to confirm the Ac-mep-l cDNA and the full length coding region of Ac-mep-l was PCR amplified (clone FL-1) under the conditions described above as a single fragment utilizing suitable primers.
- Sequence analysis Alignment of the partial Ac-mep-l clones was conducted using MEGALIGN software from DNASTAR Inc. (version 3.7.1).
- BLAST analysis of the initial sequences used for degenerate primer design and the predicted open reading frame (ORF) of Ac-mep-l was conducted using the National Center for Biotechnology Information BLAST utility.
- the induced cell pellets were frozen (BL21(DE3)PlysS cells lyse after freezing), resuspended in one-tenth vol. of 50 mM tris pH 8.0, 2 ⁇ M EDTA, sonicated until no longer viscous and then centrifuged at 12, 000 xg for 15 min (Sorvall RC5B, GSA rotor). The resulting pellet was resuspended in 15 ml 1% SDS, 0.5%> B-mercaptoethanol, sonicated, boiled for 5 min, and then incubated at room temperature for 2 h. Undissolved debris was removed by repeat centrifugation.
- mice The supernatant was dialyzed exhaustively against phosphate buffered saline (pH 7.4) to remove the BME.
- the protein was purified on HisBind ( ⁇ ovagen) nickel resin affinity column according to the manufacturer's protocol without denaturant.
- Groups of five male Balb/c mice (6-week-old) were immunized intraperitoneally with 20 ug of alum-precipitated tAc- MEP-1 or alum alone as control. The mice were subsequently boosted twice at 2-week intervals.
- sera was collected, pooled, and used as a primary antibody in the western blot and immunostaining analysis.
- the membrane was then washed three times in blocking buffer (10 min each), and incubated for 1 h at RT with horseradish peroxidase- conjugated goat anti-mouse IgG secondary antibody (1 :5000) in blocking buffer with shaking. Finally, the membrane was washed three times in PBS for 15 min and developed with Renaissance ( ⁇ E ⁇ Life Science Products) chemiluminescent reagents.
- Immun ⁇ localization Adult A. caninum worms were paraffin embedded and sectioned by standard methods.
- In situ immunolocalization of Ac-MEP-1 was accomplished by incubating de-parrafinized worm sections in a 1:100 dilution (in PBS, pH 7.4) of mouse anti-tAc-MEP-1 or control sera (see above) for 1 h at RT. The sections were washed three times in PBS and incubated in a 1 :200 dilution of goat anti-mouse IgG at 25 °C for 1 h followed by washing in PBS (three times). Sections were then visualized with a Olympus IX-50 inverted fluorescence microscope (U-MWIG filter) and photographed.
- U-MWIG filter Olympus IX-50 inverted fluorescence microscope
- G-MEP a genomic D ⁇ A clone of Ac-mep- 1 like sequence (98.7%) exon identity
- G-MEP a genomic D ⁇ A clone of Ac-mep- 1 like sequence (98.7%) exon identity)
- This prediction extended 158 bp beyond the 5' RACE sequence and increased the deduced coding region by 91 amino acids. Utilizing this prediction the entire coding region of Ac-mep-l was amplified as a single product of 2.7 kb product and the clone was confirmed by partially sequencing both its ends.
- the total length of the Ac-mep-l transcript is -2.8 kb as verified by Northern blot (non-coding portions of the 5' and 3' ends were not amplified in the full length PCR).
- the N- terminal amino acids of Ac-MEP-1 comprise a hydrophobic signal peptide sequence with a predicted cleavage after residue 22 (SEE Figure with AC-MEP-1 sequence). Two signature zinc-binding motifs characteristic of the Endopeptidase 24.11 family of metalloproteases (Hooper, 1994) were identified.
- Ac-mep-l is 66% similar and 48% identical to a metalloprotease (Hc-MEPlb) from the related trichostrongyle blood feeding nematode H. contortus. It is also equally similar to a metalloprotease (T25B6.2) from the non-parasitic nematode C. elegans (Gen-BankTM T28906). Fourteen cysteine residues are highly conserved between these three molecules. Two additional cysteines (only one is conserved) are present in both Ac-MEP-1 and Hc- MEPlb.
- Northern blot and developmental analysis of Ac-mep-l expression Northern blot analysis reveals a single mRNA transcript of approximately 2.8 kb in adult hookworm mRNA (not shown).
- RT-PCR was employed to investigate the developmental specificity of Ac-mep-l transcription.
- cDNAs tested it was possible to identify transcription only in the adult stage of the parasite and not in hookworm eggs, LI or activated and non-activated L3 larvae.
- positive control PCR conducted on the same cDNAs with primers specific for A. caninum protein kinase A revealed amplification from all template cDNAs.
- Ac-mep-l appears to be expressed exclusively in adult worms.
- MEP-1 is an important enzyme which allows hookworms to digest blood, and therefore is an attractive vaccine target.
- the recombinant MEP-1 protein has been cloned and expressed.
- Infective third-stage Ancylostoma hookworm larvae release a zinc-dependent metalloprotease that migrates with an apparent molecular weight of 50 kDa (Hawdon et al 1995a).
- the enzyme is released specifically in response to stimuli that induce feeding and development in.the L3 (Hawdon et al, 1995b), and probably functions either in parasite skin and tissue invasion or ecdysis (Hotez et al, 1990).
- an anti-enzyme antibody response directed against Ac-MTP-1 might block larval migrations and parasite entry into the intestine.
- Ac-MTP- 1 is stage specific, and released by hookworm L3activated under hostlike conditions to resume feeding in vitro. Release of Ac-MTP- I during activation makes this molecule an attractive vaccine target.
- Example 3A Isolation of a cDNA from an A. caninum L3expression library that encodes a zinc-metalloprotease (Ac-mtp-1) of the astacin family.
- Antisera Sera used for immunoscreening of the A. caninum L3 expression library were collected from 5 residents of Nanlin county in Anhui province, China, under an IRB- approved human investigations protocol. Ancylostoma duodenale is the predominant hookworm in this region, with a ratio of A. duodenale to Necator americanus of greater than 20:1 based on the recovery of larval and adult hookworms from infected patients (Yong et al. 1999). Sera were obtained from Anhui residents who had high titers of circulating antibodies to A. caninum L3 whole lysate antigens, as described elsewhere (Xue et al., 2000).
- the blocked membrane was incubated with a 1 :100 dilution of pooled human sera in PBS for 1 hr at 22 C, washed 3 times in PBS for 10 min at 22 C, and incubated with a 1:1000 dilution of horseradish peroxidase conjugated anti-human IgG (Sigma, St. Louis MO).
- the membrane was developed with substrate of 3,3'-diaminobenzidine (DAB) and 0.0 15 %> hydrogen peroxide.
- Positive plaques were subjected to several rounds of plaque purification by re-plating and re-screening. Plasmids were rescued by in vivo excision (Short and Sorge, 1992) and both strands sequenced using primers complementary to flanking vector sequence. Nucleotide and deduced amino acid sequences were compared to existing sequences in the GeneBank database by BLAST searching (Altschul et al., 1997).
- stage-specificity ofmtp-1 transcription was determined by RT-PCR (Hawdon et al, 1995).
- caninum eggs were isolated from the feces of infected dogs by sucrose floatation (Nolan et al, 1994), axenized by treatment with NaOCl, and plated on nematode growth medium agar plates (Sulston et al. 1988). Following incubation at 26 C for 24-30 h, the hatchlings (mixed L ⁇ L,) were washed from the plates with BU buffer (Hawdon and Schad, 1991) and snap-frozen in a dry ice/ethanol bath. Unhatched eggs were also snap frozen to make cDNA.
- BU buffer Hawdon and Schad, 1991
- caninum adults were collected from the small intestine of an infected dog at necropsy.
- RT-PCR was performed on A. caninum eggs, mixed Lj/L 2 serum- stimulated and nonstimulated L 3 (see below), and adult A. caninum samples as follows. Samples were ground to a powder in a pre-chilled (liquid N 2 ) mortar, and total RNA isolated using the TRIzol reagent (Life Technologies, Gaithersburg, MD) according to the manufacturer's instructions. The RNA was treated with 10 U DNAse 1 (RNase free, Boehringer Mannheim, Indianapolis, IN) and reextracted with TRIzol.
- Total egg RNA was isolated by mechanical disruption with glass beads in the presence of TRIzol using a BeadBeater machine (BioSpec, Bartlesville, OK), DNAse treated, and re-extracted as above.
- First strand cDNA was synthesized from each sample in a 50 ⁇ L reaction containing 50 mM Tris HCl, pH 8.3, 75 mM KCI, 3mM MgCl 2 , 10 mM DTT, 500 ng oligo(dT) primer, 1 ⁇ g of total RNA, and 200 U of Moloney murine leukemia virus reverse transcriptase (Life Technologies) at 37 C for 1 hr.
- the reaction was incubated at 94 C for 5 min, and brought to 100 ⁇ L with dH 2 0.
- One ⁇ L of the first strand cDNA was used in a PCR with primers MTP5'- I (5'-CTTCTCATGATCAACAAACACTACG) SEQ ID NO. 65 and MTP3'-1 (5'- AATCTAACTCCAACATCTTCTGGTG) SEQ ID NO. 66.
- the reaction was cycled 30 times for 1 min at 94 C, I min at 55 C, and 1 min at 72 C. Amplicons were separated by agarose gel electrophoresis and visualized by staining with ethidium bromide.
- rMTP-1 For purification of rMTP-1, a cell pellet from 2 1 of induced bacterial culture was suspended in 60 ml of 1.0% SDS, 0.5% 2-mercaptoethanol, boiled for 5 min, and cooled to room temperature. The extract was dialyzed against 2 liters of 0.1 %SDS in PBS for 48 hr with 2 changes of buffer, and applied to a 10 ml HisBind nickel resin column (Novagen). Chromatography was conducted according to the manufacturer's instruction except that 0.1%) SDS was added to all buffers.
- Mouse antiserum was adsorbed against bacterial lysates of E. coli strain BL21 to remove antibodies reacting with bacterial proteins. Twenty-five ml of induced cells were centrifuged, dissolved in 25 mis of 2X sample buffer (100 mM Tris, pH6.8, 2% SDS, 2.5% 2- mercaptoethanol), and centrifuged at 12,000 x g for 10 min. Nitrocellulose membranes (4 cm x 8 cm) were soaked in the supernatant for 20 min, followed by incubation in transfer buffer (48 mM Tris, 39 mM glyine, 0.037% SDS, 20% methanol) for 30 min.
- 2X sample buffer 100 mM Tris, pH6.8, 2% SDS, 2.5% 2- mercaptoethanol
- L3 collected from coprocultures were decontaminated with 1% HCl in BU buffer (Hawdon and Schad, 1991) for 30 min at 22 C. Approximately 5000 L 3 were incubated at 37 C, 5% CO 2 for 24 hr in 0.5 ml RPM 1640 , tissue culture medium supplemented with 25 mM HEPES pH 7.0, and antibiotics (Hawdon et al., 1999) in individual wells of 24-well tissue culture plates. L3 were activated to resume feeding by including 15% (v/v) of a ⁇ 10 kD ultrafiltrate of canine serum and 25 mM S-methyl-glutathione (Hawdon et al, 1995). Non-activated L 3 were incubated in RPMI without the stimuli. The percentage of feeding larvae was determined as described (Hawdon et al, 1996).
- the membrane was washed 3 times with wash buffer for 10 min at 24 C, followed by incubation with a 1:5000 dilution of horseradish peroxidase-conjugated goat anti-mouse Ig (Boehringer Mannheim, Indianapolis, IN) for 1 hour at 22 C. Bands were visualized using chemiluminescent detecting reagents (ECL+, Amersham. Pharmacia Biotech, Piscataway, NJ). Results for Example 3A.
- caninum L3 cDNA expression library was screened using pooled sera with high anti-hookworm L3 titer collected from human patients in endemic regions of China. Twelve positive clones were identified, 6 of which were identical as determined by DNA sequencing. Each clone contained a 3'poly-A tail, but was truncated at the 5' end. The 5' end was isolated from A. caninum L 3 cDNA by PCR using a primer derived from the nematode spliced leader (Hawdon et al., 1995; Bektech et al., 1988) together with the gene-specific primers PI.
- the full length cDNA, without the poly(dA) tail, is 1703 bp (see Figure 8 A, SEQ ID NO. 15) and encodes a 547 amino acid open reading frame (see Figure 8B, SEQ ID NO. 16) with a calculated molecular weight of 61,730 and a pi of 8.72.
- the ATG start codon begins 2 nt downstream from the end of the spliced leader sequence, resulting in a total of 23 untranslated nt at the 5' end of the Ac-mtp-1 cDNA.
- a TAA stop codon is located at nt 1666- 1668, followed by a 35 bp 3' UTR containing an AATAAA polyadenylation signal (Blumenthal and Steward, 1997) 12 bp upstream (bases 1687-1692) from the poly(dA) tail.
- Amino acids 1 through 16 of the deduced protein sequence are predicted to represent a hydrophobic signal peptide, with a potential cleavage site between Ala,6and Gly,7 (Nielson et al, 1995).
- the deduced sequence contains 2 potential N-linked glycosylation sites (N-X-S/T) at Asn39 and Asnl59.
- a BLAST search (Altschul et al, 1997)of GenBank using the Ac-MTP-1 predicted amino acid sequence indicated significant homology to members of a family of zinc metalloproteinases called the astacins (Bond and Benyon, 1995), named for the digestive protease astacin from the crayfish Astacus astacus.
- a search of the protein structure databases (Apweiler et al, 2000) with the Ac-MTP-1 deduced amino acid sequence revealed the presence of characteristic astacin fingerprints, including the extended zinc binding domain and a conserved Met turn located 37 amino acids downstream.
- the catalytic domain containing the zinc binding site is followed by a domain with homology to epidermal growth factor (EGF), from amino acids 334 to 368.
- EGF epidermal growth factor
- From amino acids 374 to 484 is a domain with weak homology to the CUB domain, named for its occurrence in complement subcomponents Clr/Cls, embryonic sea urchin protein C/egf, and 2?MP- 1.
- the EGF and CUB domains are common in astacin metalloproteinases, and are believed to be involved in protein-protein interactions (Bond and Benyon, 1995).
- N-terminal signal peptide is a 119 amino acid, helix-rich pro-peptide domain.
- the C-terminal end of the propeptide domain contains a 4 basic amino acid sequence (R-E-K-R) from amino acids 132 to 135 that is a potential recognition site for furin or other trypsin-like processing enzymes (Bond and Benyon, 1995). Proteolysis at this site would activate Ac-MTP- 1 to a putative 412 amino acid processed form with a calculated MW of 46419 and a pi of 8.04.
- stage-specificity of Ac-mtp-l expression was investigated by qualitative RT-PCR of cDNA from several developmental stages of A. caninum.
- Ac-mtp-l specific primers were designed to amplify a 434 bp portion of the Ac-mtp-l cDNA corresponding to nt 985 -1419 of the complete sequence.
- the product of the predicted size was amplified from both non-activated and activated L 3 cDNA, but not from A. caninum egg or L,/L 2 mixed stage cDNA. A band of lesser intensity was seen in adult cDNA.
- Recombinant MTP- 1 was produced in E. coli, purified by Ni column chromatography, and used to immunize BALB/c mice for the production of specific antiserum. The antiserum was adsorbed against E. coli lysates and used to determine if Ac-MTP-1 is secreted by A. caninum L 3 in vitro. ES products from 10,000 non-activated (non-feeding) and activated (feeding) L 3 were analyzed by Western blotting using the rMTP-1 antiserum. The antiserum recognizes both the full length and processed (i.e. without the pro-peptide domain) forms of rMTP-1 expressed in E. coli BL21 (DE3) cells but fails to recognize any bands in lysates of induced cells containing the vector alone.
- the rMTP antiserum recognized bands of MW, of 47.5 and 44.5 in the ES products of 10,000 A. caninum L3 that had been activated to resume feeding in vitro.
- the antiserum failed to recognize any bands in ES from 10,000 non-activated L 3 in culture medium alone, or in adult A. caninum ES products or worm lysates (not shown).
- a slower migrating band in activated ES has a MW similar to that of the processed form of rMTP (47.5 versus 46.5), indicating that A. caninum L 3 release processed MTP-1 during in vitro activation.
- the lower MW band was also recognized by pre-immune mouse serum (not shown), suggesting that the antiserum recognized a protein unrelated to Ac-MTP-1.
- the mouse antiserum was adsorbed against BL21 (DE3) cells expressing full length MTP-1 and used to probe the Western blot.
- Serum from hookworm-infected patients in China was used as a probe to carry out the isolation and characterization of a cDNA from an caninum L3 expression library that encodes a zincmetalloprotease (Ac-mtp-l) of the astacin family.
- the amplified sequence is believed to represent the complete 5' end of the transcript because the predicted ATG start codon is the first methionine following the spliced leader, the first 16 deduced amino acids encode a signal peptide characteristic of secreted proteins (Nielson et al., 1997), and alignments with similar metalloproteases suggest that this is the complete amino acid sequence.
- the full length cDNA, without the poly(dA) tail, is 1703 bp and encodes a 547 amino acid open reading frame with a calculated molecular weight of 61,730 and apl of 8.72.
- Amino acids 1 through 16 of the deduced protein sequence are predicted to represent a hydrophobic signal peptide, with a potential cleavage site between Alal6 and Glyl7 (Nielson et al., 1997).
- the protein sequence contains two potential N-linked glycosylation sites (NX- S/T) at Asn39 and Asnl59.
- NX- S/T N-linked glycosylation sites
- a BLAST search Altschul et al, 1997) of GenBank using the Ac-MTP-1 predicted amino acid sequence indicated significant homology to members of a family of zinc metalloproteinases called the astacins (Bond and Beynon, 1995), named for a digestive protease from the crayfish Astacus astacus.
- the catalytic domain containing the zinc binding site is followed by a domain with homology to epidermal growth factor (EGF), from amino acids 334 to 368.
- EGF epidermal growth factor
- From amino acids 374 to 484 is a domain with weak homology to the CUB domain, named for its occurrence in complement subcomponents Clr/Cls, embryonic sea urchin protein Uegf, and BMP-1 (Bork and Beckman, 1993).
- Astacin metalloproteinases are synthesized as inactive proenzymes. Removal of the pro-peptide by a processing enzyme activates the enzyme (Bond and Beynon, 1995).
- Ac- MTP-1 contains a 119 amino acid N-terminal domain with a predicted four amino acid recognition site (R 132 E ]33 K ]34 R 135 ) for a trypsin- or furin-type processing enzyme at its C- terminus (Bond and Beynon, 1995). Proteolysis at this site would activate Ac-MTP-1 to a putative 412 amino acid processed form with a calculated MW of 46,419 and a pi of 8.04.
- the pro-peptide is also predicted to contain four amphipathic ⁇ -helices separated by a short linker region (amino acids 23-86) (Kelley et al, 2000).
- the stage-specificity of Ac-mtp-l expression was investigated by qualitative RT-PCR of cDNA from several developmental stages of A. caninum. Specific primers were designed to amplify a 434 bp portion of the Ac-mtp-l cDNA corresponding to nucleotides 985-1419 of the complete sequence.
- a product of the predicted size was amplified from both non- activated and activated L3 cDNA, but not from A.
- Recombinant MTP-1 was produced in Escherichia coli, purified by Ni column chromatography, and used to immunize BALB/c mice for the production of specific antiserum.
- the antiserum was adsorbed against E. coli lysates and used to determine if Ac- MTP-1 is secreted by A. caninum L3 in vitro.
- ES products collected from 10,000 non- activated (non-feeding) and activated (feeding) L3 were analyzed by Western blotting using the rMTP-1 antiserum.
- the antiserum recognizes both the full length and processed (i.e. without the pro-peptide domain) forms of rMTP-1 expressed in E.
- the rMTP antiserum recognized bands of Mr of 47.5 and 44.5 in the ES products of 10,000 A. caninum L3 that had been activated to resume feeding in vitro.
- the antiserum failed to recognize any specific bands in ES from non-activated L3, in culture medium alone, or in adult A caninum ES products or worm lysates (not shown).
- a slower migrating band in activated ES had a Mr similar to that of the processed form of rMTP (47.5 vs. 46.5), indicating that caninum L3 release processed MTP-1 during in vitro activation.
- MTP-1 is released only in response to stimuli that activate L3 to resume feeding, and therefore, most likely functions at some stage of the infective process (Hawdon et al, 1996).
- the metalloproteolytic activity described previously was also released specifically during activation, and was of similar molecular size (Hawdon et al., 1995), suggesting that Ac-MTP-1 might be responsible for at least a portion of this activity.
- MTP-1 is an important enzyme used by the hookworm parasite for invasion, and the protein is an immunodominant antigen because it is recognized by serum from patients with low hookworm burden despite repeated exposure to hookworm. MTP is therefore an attractive candidate for a vaccine antigen.
- Example 3C Canine vaccine trials with Ac-MTP-1 antigen
- solubilized inclusion bodies that were solubilized in 6 M guanidine-HCl in 10 mM Tris HCl, pH 8.0.
- the solubilized inclusion bodies were processed in 5-10 ml batches by gel filtration chromatography (Sephacryl S-300, 26/60 gel filtration column [Amersham Pharmacia] pre-equilibrated in a buffer containing 0.1 NaH2PO4, 10 mM Tris-HCl and 6 M guanidine) at room temperature (flow rate of 2 ml/minute).
- the column was subsequently washed with 15 column volumes of equilibration buffer, and the bound protein was eluted with 50 mM sodium phosphate pH7.2, 1 M urea, 0.5 M NaCI, and 50 mM ethylenediamine tetraacetic acid ( ⁇ DTA). Eluted samples containing protein were pooled and dialyzed against 10 mM Tris-HCl pH 8.0, 5% glycerol, 1 mM dithiothreitol, and 2 mM EDTA. The purified recombinant Ac-MTP-1 did not exhibit enzymatic activity (data not shown).
- the recombinant Ac-MTP-1 fusion protein was mixed with SBAS2 adjuvant and administered to each of five dogs in four intramuscular injections on days 1, 4, 43, and 50. Each dog received approximately 140 ⁇ g of recombinant fusion protein and 0.5 ml of ASO2A per dose. Five dogs were also injected intramuscularly with AS02A on the same schedule. Following immunization, blood was collected weekly by venipuncture and the serum was separated and stored frozen at -20°C. Antigen-specific canine IgG2 and IgE antibodies were measured by indirect enzyme-linked immunosorbent assay (ELISA) as described previously (Hotez et al, 2002a).
- ELISA indirect enzyme-linked immunosorbent assay
- Serum chemistries were also obtained at the end of the vaccination schedule and prior to necropsy.
- Quantitative hookworm egg counts (McMaster technique) on each dog were obtained 3 days per wk beginning on day 12 post-infection (PI). Five wk post-infection, the dogs were killed by intravenous barbituate injection, and the adult hookworms were recovered and counted from the small and large intestines at necropsy (Hotez et al., 2002c). The statistical significance of differences between adult hookworm burdens was determined using the Anova test, as were differences in hematological parameters and in quantitative hookworm egg counts. Comparisons of hookworm burden and egg counts with antibody titers were measured using Spearman rank order (nonparametric) correlations.
- Sera from the vaccinated dogs recognized a triplet of closely migrating proteins with the predicted molecular weight of the proenzyme and processed form of Ac-MTP-1 in secretory products of host-activated L3, but not in those of non-activated L3.
- the additional bands may also correspond to other related metalloproteases secreted by A. caninum L3; at least 3 closely related expressed sequence tags from A. caninum L3 were found in a dbEST database (ncbi.nim.nih.gov/dbEST/index.html).
- the number of hookworms recovered from the dog with the highest antibody titer (98 hookworms) was equivalent to a 50 percent reduction in worm burden compared to the number of adult hookworms recovered from the dog with the lowest antibody titer (189 hookworms).
- An identical relationship was noted between IgG2 antibody titers and median quantitative egg counts (Fig. 33B).
- Study dogs and animal husbandry Following protocol approval by The George Washington University Institutional Animal Care and Use Committee (IACUC), purpose bred, parasite na ⁇ ve, male beagles 8 + 1 week of age were purchased, identified by ear tattoo, and maintained in the AALAC (Association for Assessment and Accreditation of Laboratory Animal Care) accredited George Washington University Animal Research Facility.
- the dogs were housed in a room dedicated for the study, at a room temperature of 70 + 4°F, with 10-15 air changes per hour comprised of 100 percent fresh air, and 12 hr light cycles alternating with 12 hr dark cycles. The airflow and timer functions were monitored daily.
- the dogs were fed on a diet of Teklad Certified Dog Chow #8727, supplemented with a canned soft diet in the event of anorexia.
- the drinking water was piped from a filter plant and delivered via automate water system; water analysis was performed by the U.S. Army Corps of Engineers. Water from the facilities automatic system is cultured for bacteria and fungi annually.
- the pens were flushed daily and sanitized every two weeks. Dogs within a given study group were permitted to live together and socialize prior to the hookworm larval challenge, but were caged individually post-infection. All dogs were quarantined for approximately one week before beginning the vaccine trial. Prior to vaccination a complete blood count (CBC), serum chemistries, and a pre-vaccination serum sample were obtained.
- CBC complete blood count
- Recombinant Antigens Each group of 6 dogs was vaccinated with recombinant hookworm proteins expressed as fusion proteins either in Escherichia coli or in an insect cell line with baculovirus.
- Ac-AP (Cappello et al, 1995; 1996) and Ac-TMP, were expressed in E.coli as pET 28 (Novagen) fusion proteins containing a polyhistidine tag (Cappello et al, 1996).
- Ac- APR-1 (Harrop et al, 1996) was expressed in a baculovirus pBacPAK6 vector (Clontech), modified to contain a polyhistidine-encoding sequence and additional restriction enzyme sites (Brindley et al, 2001).
- Recombinant Ac-AP and Ac-TMP fusion proteins were then purified by nickel affinity chromatography, followed by a second step of purification.
- the recombinant protein was purified by mono-S (Amersham-Pharmacia) ion exchange chromatography, while Ac-TMP (Zhan et al, 2002) was purified by superdex 75 (Amersham-Pharmacia) gel filtration chromatography.
- Ac-APR-1 (Harrop et al, 1996) was purified by substrate affinity chromatography using pepstatin agarose (Brindley et al, 2001).
- the antigen stock protein concentration was determined by Pierce Micro BCA assay (Pierce Chemicals) or by the absorbance of the sample at 289 nm using an extinction coefficient that was calculated from the deduced amino acid composition of the fusion protein.
- the amount of alum adsorbed protein in each dose of antigen was measured by the Pierce Micro BCA assay using a bovine serum albumin standard.
- the relative purity of each of the antigens relative to contaminating E. coli or insect cell proteins was determined by analysis on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
- Adjuvant formulations Recombinant Ac-TMP and Ac- APR fusion proteins were alum precipitated with a combination of aluminum potassium sulfate dodecahydrate and sodium bicarbonate as described previously (Ghosh et al, 1996). The method requires the precipitation of an aqueous solution of the protein with aluminum salt under alkaline conditions, followed by centrifugation and washing (Ghosh and Hotez, 1999). Using this method, recombinant Ac-AP fusion protein was not detected in the alum precipitate. Therefore, the first two doses of Ac-AP were administered without adjuvant. However, the final two doses of Ac-AP were adsorbed to an amorphous, non-crystalline calcium phosphate gel.
- Canine Immunizations A four-dose immunization schedule was selected (Table II). Each of the dogs was vaccinated by subcutaneous immunization at two sites in the shoulder, through a 22 gauge needle. The volume of the injections ranged between 0.5 and 1.0 ml. Four doses of each antigen were administered over a 38-day period. The first two injections (primary immunization) were administered on days 1 and 4, and the final two immunizations (boosts) were administered on days 34 and 38. Dogs in the control group were injected with an equivalent amount of alum.
- Canine antibody measurements Blood was collected weekly by venipuncture and the serum was separated and stored frozen at -20°C.
- Antigen-specific canine IgGl antibodies were measured by indirect enzyme-linked immunosorbent assay (ELISA). Other IgG subclasses were not measured due to the unavailability of suitable high-quality canine- specific reagents.
- the optimal concentrations of sample sera and enzyme-linked detection antibody were determined by checkerboard titrations. Optimal antigen concentrations were determined by using a saturation technique. NUNC Maxisorp F96 certified plates (Rosklide, Denmark; Batch no. 045638) were coated with 0.1 ml per well of antigen in 0.05M carbonate bicarbonate buffer (pH 9.6).
- hookworm strain used for the study is described elsewhere (Hotez et al, 2002). Validation of the hookworm species used in the study was confirmed by a polymerase chain reaction followed by restriction fragment length polymorphism (Hawdon, 1996). Following infection, the dogs were bled weekly by venipuncture in order to obtain a complete blood count (CBC). Serum chemistries were also obtained at the end of the vaccination schedule and prior to necropsy. Quantitative hookworm egg counts (McMaster technique) on each dog were obtained three days per week beginning on day 12 post-infection.
- a caninum antigens Three recombinant A. caninum antigens were selected for canine vaccinations. Two of them, Ac-AP and Ac-TMP are protease inhibitors secreted only by adult stage hookworms.
- Ac-AP is a 91 amino acid factor Xa inhibitor anticoagulant (Cappello et al, 1995; 1996)
- Ac-TMP is a 140 amino acid putative tissue inhibitor of metalloproteinase, and the most abundant protein secreted by A. caninum.
- a canine vaccination schedule was selected that provided for a primary immunization to be administered in two subcutaneous doses over an initial 4-day period (day 1 and day 4), followed by two subsequent subcutaneous immunization boosts that were administered beginning 30 days after the primary immunizations (day 34 and day 38).
- Ac-TMP and Ac-APR-1 were injected as alum-precipitated proteins.
- Ac-AP did not form a precipitate with alum. Therefore, for the first two doses, Ac-AP was administered subcutaneously without adjuvant.
- a protocol that employed calcium phosphate gel was shown to effectively precipitate Ac-AP (data not shown). For that reason, calcium phosphate was selected as the adjuvant for the final two immunizing doses of Ac-AP.
- Dogs vaccinated against Ac-TMP also exhibited a reduction in the adult hookworm burden (10.8 percent) although this was not statistically significant.
- the five dogs that did not exhibit an antibody response against Ac-AP also exhibited no significant hookworm burden reduction.
- the single dog with a significant anti- Ac-AP antibody response exhibited a 34.7 percent reduction in adult hookworm burden.
- Table III data did not provide sufficient evidence for statistically significant reductions " in quantitative hookworm egg counts between the vaccinated and control dogs.
- vaccination did not affect the hematological parameters of the dogs, including hematocrit, hemoglobin, white blood cell count, and eosinophilia (data not shown).
- Sex determinations were not made on the hookworms attached to a 1-2 cm segment of small intestine that was saved for histopathological analysis.
- the mean number of hookworms in this segment ranged between 5 and 6 worms. This small number of worms did not contribute significantly to the sex-dependent difference score (data not shown).
- This example demonstrates that it is feasible to vaccinate mammals with recombinant fusion proteins to elicit an antigen specific response, and that the antibody response is associate either with a hookworm burden reduction in the gut or in a shift in hookworm habitat in the gut.
- EXAMPLE 5 Canine Vaccine Trials of Ac-MTP-1 and Ac-TTR Example 5A. Antibody titers and hookworm reduction.
- E. coli derived antigens Ac-MTP-1 and Ac-TTR were tested in vaccine trials in dogs. Antigens were administered with adjuvant SBAS2. The vaccinated animals exhibited high levels of canine IgG2 antigen-specific antibodies, and a modest increase in antigen-specific IgE. Subsequently the dogs were challenged by subcutaneous injection of L3 hookworm larvae.
- Sera from the vaccinated dogs recognized a triplet of closely migrating proteins with the predicted molecular weight of the proenzyme and processed form of Ac-MTP-1 in secretory products of host-activated L3, but not in those of non-activated L3.
- TTR antigen As can be seen in Figures 37A and B, one dog with high IgE and IgGl antibody to TTR exhibited reduced (6% ⁇ ) hookworm burden.
- This example demonstrates that vaccination of mammals with either MTP or with TTR elicit a protective antibody response, and that with high antibody titers a reduction in worm burden is observed.
- Example 5B Protection against blood loss and decrease in hookworm size due to vaccination with hookworm antigen
- ICC- 1546 expresses ASP-1 amino acids 291-303 as a "looped out" tethered structure, whereas ICC- 1564 expresses the same peptide as an N-terminal structure. Previous studies had demonstrated that mouse anti-L3 antibody recognizes ICC-1546, but not ICC-1564.
- the antigenic chimeras were administered as described above with alhydrogel as adjuvant.
- DSM detergent solubilized membrane extract of adults, caninum
- Larval challenge was carried out by subcutaneous injection of L3 stage larvae.
- EXAMPLE 7 Antigen expression in baculovirus/insect cells and yeast
- hookworm antigens in eukaryotic expression systems such as baculovirus/insect cells and the yeast Pichia pastoris, have been carried out to afford maximum opportunities for obtaining soluble and bioactive recombinant proteins.
- the antigens Na-ASP-1, Ac-TTR, Ac- API, and Ay-ASP-2 have been successfully expressed with Pichia fermentation systems. Antigens were isolated with polyhistidine tags for ease of isolation.
- Antigens Na-CTL, Ac-MEP-1, Ac-ASP-2 and Ac-MTP-1 have been successfully expressed in a baculovirus/insect cell expression system. Antigens were isolated with polyhistidine tags for ease of isolation. EXAMPLE 8. Cloning of cDNAs of A. ceylancium Orthologous Antigens Ay-ASP-1,
- Orthologous antigens from the hamster parasite hookworm A. ceylancium were successfully cloned following the construction of an A. ceylancium larval cDNA library.
- the ceylanicum orthologue of ASP-1 was cloned by screening the A. ceylanicum L3 cDNA library using a 900bp 32 P- labeled Ac- ASP 1 cDNA fragment as a probe. Screening of approximately 500,000 clones resulted in 85 positive clones. Of these 21 clones were sequenced of which 19 encoded identical cDNAs. No other orthologues of ASP-1 were found. The clones exhibited 85% identity and 92%) similarity with Na-ASP-1.
- Immuno localization of some of the major vaccine antigens was carried out in sections of adult hookworms.
- the immunolocalizations were determined to be as follows: Ac-103 as a hookworm surface antigen, Ac-FAR-1 and Ac- API as components of the pseudocoelomic fluid, (Ac- API is also a pharyngeal protein), Ac-CP-1 as an amphidial gland protein, Ac-TMP in the excretory glands, and ASP-3 as an amphidial and esophageal protein.
- Ac-103 as a hookworm surface antigen
- Ac-FAR-1 and Ac- API as components of the pseudocoelomic fluid
- Ac- API is also a pharyngeal protein
- Ac-CP-1 as an amphidial gland protein
- Ac-TMP in the excretory glands
- ASP-3 as an amphidial and esophageal protein.
- the total proteins of the hookworm ES products localized to amphidial and excretory glands, and to the brush border
- hookworm antigens are exposed either on the surface of the worm or secreted by worm and are therefore susceptible to targeting by host antibodies or host immunocompetent cells.
- Figs. 40 and 41 CD-4 + lymphocytes were gated from the whole blood of hookworm infected residents and stimulated with either L3 soluble hookworm antigen Fig. 40) or Pichia-expressed recombinant Na-ASP-1 (Fig. 41). Host cytokine production was measured by an intracellular cytokine staining technique. Both antigens stimulated high levels of IL-10 and IL-5, but not IL-4. IL-10 is a strong immunomodulator with downregulatory, anti-inflammatory properties, and IL-4 is associated with antibody production and TH-2 type immunity. The findings suggest that hookworm infected individuals might be anergic to hookworm and possibly other antigen stimulation.
- hookworm infection might thwart otherwise successful vaccinations against such etiological agents as HIV and malaria.
- it may become essential to monitor a study participant's hookworm status prior to HIV or malaria vaccination, and to treat those that are found to be actively infected prior to immunization.
- Hotez P B. Zhan, J. Qun, J.M. Hawdon, H.A. Young, S. Simmens, R. Hitzelberg, and B.C. Zook. 2002c. Natural history of primary canine hookworm infections following 3 different oral doses of third-stage infective larvae of Ancylostoma caninum. Comparative Parasitology 69:72-80. Hotez PJ, Feng Z, Xu LQ, Chen MG, Xiao SH, Liu SX, Blair D, McManus DP, Davis GM. 1997. Emerging and reemerging helminthiases and the public health of China. Emerg. Infect. Dis. 3:303-10.
- Kelley LA MacCallum RM, Sternberg MJ. 2000. Enhanced genome annotation using structural profiles in the program 3D-PSSM. JMol Biol 299:499-520.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002335061A AU2002335061A1 (en) | 2001-10-17 | 2002-10-17 | Hookworm vaccine |
BRPI0213656-2A BR0213656A (en) | 2001-10-17 | 2002-10-17 | composition, method for obtaining an immune response to tapeworm, method for vaccinating a mammal against tapeworm, vaccine, method for allowing vaccination, methods for reducing blood loss, reducing tapeworm size and reducing distress by tapeworm in a patient infected with tapeworm, synthetic recombinant antigen and antigen |
US10/825,692 US7303752B2 (en) | 2001-10-17 | 2004-04-16 | Hookworm vaccine |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32953301P | 2001-10-17 | 2001-10-17 | |
US60/329,533 | 2001-10-17 | ||
US33200701P | 2001-11-23 | 2001-11-23 | |
US60/332,007 | 2001-11-23 | ||
US37540402P | 2002-04-26 | 2002-04-26 | |
US60/375,404 | 2002-04-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/825,692 Continuation-In-Part US7303752B2 (en) | 2001-10-17 | 2004-04-16 | Hookworm vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003032917A2 true WO2003032917A2 (en) | 2003-04-24 |
WO2003032917A3 WO2003032917A3 (en) | 2003-10-23 |
Family
ID=27406669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/033106 WO2003032917A2 (en) | 2001-10-17 | 2002-10-17 | Hookworm vaccine |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN1571677A (en) |
AU (1) | AU2002335061A1 (en) |
BR (1) | BR0213656A (en) |
WO (1) | WO2003032917A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008156650A2 (en) | 2007-06-15 | 2008-12-24 | Idexx Laboratories, Inc. | Device, kit and method for hookworm antigen capture and detection |
US7993862B2 (en) | 2008-05-19 | 2011-08-09 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
US7993861B2 (en) | 2008-05-19 | 2011-08-09 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting whipworm |
US8105795B2 (en) | 2008-05-19 | 2012-01-31 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
US8268574B2 (en) | 2008-05-19 | 2012-09-18 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
US8580518B2 (en) | 2008-05-19 | 2013-11-12 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
US8895294B2 (en) | 2007-06-15 | 2014-11-25 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm, whipworm, and hookworm |
US9239326B2 (en) | 2007-06-15 | 2016-01-19 | Idexx Laboratories, Inc. | Compositions, devices, kits and methods for detecting hookworm |
-
2002
- 2002-10-17 WO PCT/US2002/033106 patent/WO2003032917A2/en not_active Application Discontinuation
- 2002-10-17 CN CNA028207696A patent/CN1571677A/en active Pending
- 2002-10-17 AU AU2002335061A patent/AU2002335061A1/en not_active Abandoned
- 2002-10-17 BR BRPI0213656-2A patent/BR0213656A/en not_active IP Right Cessation
Non-Patent Citations (3)
Title |
---|
BIN ET AL.: 'Ancylostoma secreted protein 1 (ASP-1) homologues in human hookworms' MOLECULAR AND BIOCHEMICAL PARASITOLOGY vol. 98, 1999, pages 143 - 149, XP002964543 * |
HOTEZ ET AL.: 'Experimental approaches to the development of a recombinant hookworm vaccine' IMMUNOLOGICAL REVIEWS vol. 171, 1999, pages 163 - 172, XP001000926 * |
SEN ET AL.: 'Hookworm burden reductions in BALB/c mice vaccinated with recombinant ancylostoma secreted proteins (ASPs) from ancylostoma duodenale, ancylostoma caninum and necator americanus' VACCINE vol. 18, 2000, pages 1096 - 1102, XP001005230 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895294B2 (en) | 2007-06-15 | 2014-11-25 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm, whipworm, and hookworm |
US9239326B2 (en) | 2007-06-15 | 2016-01-19 | Idexx Laboratories, Inc. | Compositions, devices, kits and methods for detecting hookworm |
WO2008156650A2 (en) | 2007-06-15 | 2008-12-24 | Idexx Laboratories, Inc. | Device, kit and method for hookworm antigen capture and detection |
US9063129B2 (en) | 2007-06-15 | 2015-06-23 | Idexx Laboratories, Inc. | Device, kit and method for hookworm antigen capture and detection |
US9040245B2 (en) | 2007-06-15 | 2015-05-26 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm, whipworm, and hookworm |
AU2008266975B2 (en) * | 2007-06-15 | 2012-01-19 | Idexx Laboratories, Inc. | Device, kit and method for hookworm antigen capture and detection |
EP2164948A2 (en) * | 2007-06-15 | 2010-03-24 | IDEXX Laboratories Inc | Device, kit and method for hookworm antigen capture and detection |
US11267879B2 (en) | 2007-06-15 | 2022-03-08 | Idexx Laboratories, Inc. | Compositions, devices, kits and methods for detecting hookworm |
US10942180B2 (en) | 2007-06-15 | 2021-03-09 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm, whipworm and hookworm |
US10640551B2 (en) | 2007-06-15 | 2020-05-05 | Idexx Laboratories, Inc. | Compositions, devices, kits and methods for detecting hookworm |
EP2164948A4 (en) * | 2007-06-15 | 2010-12-08 | Idexx Lab Inc | Device, kit and method for hookworm antigen capture and detection |
US10429388B2 (en) | 2007-06-15 | 2019-10-01 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm, whipworm and hookworm |
US9746469B2 (en) | 2007-06-15 | 2017-08-29 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm, whipworm, and hookworm |
US8105795B2 (en) | 2008-05-19 | 2012-01-31 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
US9212220B2 (en) | 2008-05-19 | 2015-12-15 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
US9103823B2 (en) | 2008-05-19 | 2015-08-11 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
US7993862B2 (en) | 2008-05-19 | 2011-08-09 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
US7993861B2 (en) | 2008-05-19 | 2011-08-09 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting whipworm |
US8580518B2 (en) | 2008-05-19 | 2013-11-12 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
US8367808B2 (en) | 2008-05-19 | 2013-02-05 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting whipworm |
US8268574B2 (en) | 2008-05-19 | 2012-09-18 | Idexx Laboratories, Inc. | Methods, devices, kits and compositions for detecting roundworm |
Also Published As
Publication number | Publication date |
---|---|
CN1571677A (en) | 2005-01-26 |
BR0213656A (en) | 2006-05-23 |
WO2003032917A3 (en) | 2003-10-23 |
AU2002335061A1 (en) | 2003-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xiao et al. | The evaluation of recombinant hookworm antigens as vaccines in hamsters (Mesocricetus auratus) challenged with human hookworm, Necator americanus | |
US7303752B2 (en) | Hookworm vaccine | |
US8257713B2 (en) | Vaccine | |
US10314900B2 (en) | Lutzomyia longipalpis polypeptides and methods of use | |
Ramachandran et al. | The larval specific lymphatic filarial ALT‐2: induction of protection using protein or DNA vaccination | |
US8629260B2 (en) | Anti-arthropod vector vaccines, methods of selecting and uses thereof | |
CA2818027C (en) | Vaccine composition for controlling ectoparasite infestations | |
WO2003032917A2 (en) | Hookworm vaccine | |
US8444994B2 (en) | Multivalent antihelminthic vaccine | |
US7718179B2 (en) | Ostertagia vaccine | |
ZA200402953B (en) | Hookworm vaccine | |
WO2005058350A1 (en) | Novel vaccines for treating or preventing infections by echinococus parasites | |
JP4883839B2 (en) | El. Chimeric gene encoding antigenic determinants of four proteins of L. infantum | |
Jayaraj | Expression of stage-specific Fasciola proteases and their evaluation in vaccination trials | |
NZ723022B2 (en) | Sheep nematode vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10825692 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/02953 Country of ref document: ZA Ref document number: PA/a/2004/003708 Country of ref document: MX Ref document number: 200402953 Country of ref document: ZA Ref document number: 20028207696 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1050/DELNP/2004 Country of ref document: IN |
|
122 | Ep: pct application non-entry in european phase | ||
ENP | Entry into the national phase |
Ref document number: PI0213656 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |